Company Overview and News

 
Steel boss: Energy policy must deliver for heavy industry

22h nzherald.co.nz
Energy-intensive heavy industry has a long-term future in New Zealand, but only if policies to decarbonise the economy can deliver a secure energy supply, says the outgoing chief executive of New Zealand Aluminium Smelters, Gretta Stephens, who will swap to be CEO at Bluescope's New Zealand Steel plant later this month.

 
Shares gain as Ryman posts record profit

2018-05-18 nzherald.co.nz
New Zealand shares rose as Goodman Property Trust's joint venture with GIC sold seven buildings in downtown Auckland, and as Ryman Healthcare chalked up another record profit. A2 Milk Co and Comvita fell.

 
Time to reconvene Capital Markets Taskforce?

2018-05-16 nzherald.co.nz
It's time to reconvene the Capital Markets Taskforce and have a clear look at whether more state assets can be primed for partial privatisation through the mixed-ownership model (MOM) and beef up liquidity at the NZX.

 
Trustpower boosts annual profit 35% to $129m

2018-05-14 nzherald.co.nz
Trustpower lifted annual profit 35 per cent as the electricity generator-retailer's earnings were bolstered by favourable hydro generation, firm winter wholesale prices and its retail strategy.

 
Expert: A2 Milk could replace Fletcher Building in key sharemarket index

2018-05-13 nzherald.co.nz
Mark Lister, head of private wealth research at Craigs Investment Partners, said the announcement of Fletcher's place in the MSCI Index is due out today and we will know the result tomorrow.

 
NZX 50 hits record on outlook for low interest rates

2018-05-10 nzherald.co.nz
New Zealand shares rose to a record high, led by Pushpay Holdings and Scales Corp, after the Reserve Bank affirmed plans to keep interest rates low. Mercury New Zealand and Fletcher Building weakened.

 
Shares rise as investors second guess index changes; Fletcher gains

2018-05-08 nzherald.co.nz
New Zealand shares rose, joining a regional rally, as investors predict whether an upcoming MSCI index review will spur major activity next week. Fletcher Building, which could exit the index, gains, while new addition a2 Milk Co fell.

 
Fran O'Sullivan: Jones' new SOE job spurs unease

2018-05-04 nzherald.co.nz
There's considerable trepidation brewing within the senior business community on whether Shane Jones' appointment as Associate Minister for State Owned Enterprises signals another round of knuckle-headed Beehive politics.

 
Meridian Energy and Whakatāne District Council join forces on clean energy

2018-05-04 nbr.co.nz
Credit card details are required to authenticate your account. You won't be charged until your trial has ended. Cancel anytime.

 
NZ shares up as A2 leads index

2018-05-02 nzherald.co.nz
New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.

 
NZ shares dip; Kiwi Property, Fletcher drop

2018-05-01 nzherald.co.nz
New Zealand shares fell slightly, despite a gain in energy stocks and ANZ Bank New Zealand rising on its first-half earnings.

 
MARKET WRAP: NZ shares up 0.7%, Meridian, Mercury and Chorus gain

2018-04-30 nbr.co.nz
Harbour Asset Management analyst Shane Solly says it was a strong day for the energy providers.

 
NZ shares up 1%, led by Fisher & Paykel, Kathmandu, Spark

2018-04-27 nzherald.co.nz
New Zealand shares gained, led by Fisher & Paykel Healthcare Corp and Kathmandu in broad-based buying.

 
NZ shares fall as MSCI changes debated

2018-04-20 nzherald.co.nz
New Zealand shares fell, taking a negative lead from Wall Street, as Fletcher Building's share offer weighed on demand.

 
NZ shares gain; Trade Me rises

2018-04-18 nzherald.co.nz
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...